Blum&Grob advises Therachon in financing round
Therachon Holding AG completed a further financing round thereby raising additional capital of USD 60 million. Therachon is a Basel-based clinical-stage biotechnology company focusing on rare diseases.
The financing led by Novo Holdings was joined by new investors Cowen Healthcare Investments, Pfizer Ventures and Tekla Capital Management LLC. Existing investors Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative also participated.
Blum&Grob (Christian Koller and Ralph Imoberdorf) acted as Swiss Counsel to Therachon.
For Therachon’s press release please click here.